Scarica l'app Stockscreener
2.76
1.08%
-0.03
Dopo l'orario di chiusura:
2.76
Ac Immune Sa Borsa (ACIU) Ultime notizie
ACIU Technical Analysis & Stock Price Forecast - Intellectia AI
AC Immune (ACIU) director Zuegel reports options and RSU-based share stakes - Stock Titan
Exit Recap: Can AC Immune SA deliver consistent EPS growthWeekly Trend Report & Smart Investment Allocation Tips - baoquankhu1.vn
Is AC Immune (ACIU) outperforming other medical stocks this year? - MSN
Ideas Watch: What is the long term forecast for AC Immune SA stockRate Cut & Entry and Exit Point Strategies - baoquankhu1.vn
ACIU SEC FilingsAC Immune 10-K, 10-Q, 8-K Forms - Stock Titan
ACIU Stock Price, Quote & Chart | AC IMMUNE SA (NASDAQ:ACIU) - ChartMill
AC Immune Posts 2025 Results, Sharpens Pipeline Focus and Extends Cash Runway to 2027 - TipRanks
AC Immune FY 2025 Results: Eyeing ACI-7104 Catalysts - seekingalpha.com
Trading Recap: Will AC Immune SA stock hit new highs in YEAR2026 Investor Takeaways & Fast Gain Swing Alerts - baoquankhu1.vn
AC Immune (ACIU) COO Piergiorgio Donati reports shares and long-dated options - Stock Titan
AC Immune shows first brain images of TDP-43 pathology in trial - Investing.com India
ACIU Unveils Promising Phase 1 Data for TDP-43 PET Imaging - GuruFocus
AC Immune Presents First In vivo Images of Brain TDP-43 - GlobeNewswire
Aug Volume: Does AC Immune SA outperform in volatile markets2026 Price Momentum & Growth Oriented Trading Recommendations - baoquankhu1.vn
AC Immune (ACIU) CFO discloses common shares, RSUs and option grants - Stock Titan
AC Immune (NASDAQ: ACIU) director Monika Buetler details initial share and option holdings - Stock Titan
AC Immune (NASDAQ: ACIU) director reports initial Form 3 holdings - Stock Titan
[Form 3] AC Immune SA Initial Statement of Beneficial Ownership - Stock Titan
AC Immune (ACIU) CEO discloses equity and option holdings - Stock Titan
AC Immune (ACIU) director June Carl Howard details share and option stakes - Stock Titan
AC Immune (ACIU) Upgraded to Buy: Here's Why - Yahoo Finance
Is AC Immune (ACIU) Outperforming Other Medical Stocks This Year? - Yahoo Finance
FY2026 EPS Estimates for AC Immune Lifted by HC Wainwright - MarketBeat
Trend Review: Will AC Immune SA outperform its industry peersWeekly Earnings Recap & Growth Oriented Trading Recommendations - baoquankhu1.vn
ACIU: BTIG Reiterates Buy Rating with $8 Target Price | ACIU Sto - GuruFocus
AC Immune: Advancing Neurology Pipeline and Imminent Alzheimer’s Vaccine Data Support Buy Rating - TipRanks
Jefferies Maintains Buy on ACIU (AC Immune S.A.) March 2026 - Meyka
AC Immune (ACIU) Loss Of CHF 15.9 Million Tests Bullish Profitability Narratives - simplywall.st
Jefferies reiterates AC Immune stock Buy rating on vaccine data By Investing.com - Investing.com Australia
Jefferies reiterates AC Immune stock Buy rating on vaccine data - Investing.com
AC Immune 2025 Financials: Annual Loss of $85M, Q4 Revenue $423KNews and Statistics - IndexBox
ACIU: Positive interim results for ACI-7104 and strategic focus extend cash runway to Q3 2027 - TradingView
AC Immune reports FY25 EPS (CHF 0.70) vs (CHF 0.51) last year - TipRanks
AC Immune: Fourth Quarter Financial Results Overview - Bitget
AC Immune: Q4 Earnings Snapshot - Barchart
ACIU: Net loss increased to CHF 70.4 million in 2025 as revenue declined and R&D costs remained high - TradingView
AC Immune (NASDAQ: ACIU) posts 2025 loss but flags key 2026 trial milestones - Stock Titan
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update - GlobeNewswire
AC Immune (ACIU) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
AC Immune SA expected to post a loss of 17 rappen a shareEarnings Preview - TradingView
Risk Report: What is AC Immune SAs book value per shareJuly 2025 Pullbacks & Intraday High Probability Alerts - baoquankhu1.vn
Aug Big Picture: Should I buy AC Immune SA stock nowJuly 2025 Patterns & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Hedge Fund Bets: What is the long term forecast for AC Immune SA stockJuly 2025 Closing Moves & Daily Oversold Bounce Ideas - baoquankhu1.vn
AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026 - GlobeNewswire
Inside a 2026 push to prevent Parkinson’s at AC Immune’s symposium - Stock Titan
AC Immune (NASDAQ:ACIU) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Will AC Immune SA stock hit new highs in YEAR2025 Historical Comparison & Risk Controlled Swing Alerts - baoquankhu1.vn
AC Immune (ACIU) Begins Phase 1 Trial for New Inflammation Treat - GuruFocus
AC Immune begins phase 1 trial of brain-penetrant NLRP3 inhibitor - Investing.com Nigeria
AC Immune Doses First Participant in Phase 1 Trial of NLRP3 Inhibitor ACI-19764 - TipRanks
AC Immune begins phase 1 trial of brain-penetrant NLRP3 inhibitor By Investing.com - Investing.com South Africa
AC Immune (NASDAQ: ACIU) begins Phase 1 test of NLRP3 inhibitor ACI-19764 - Stock Titan
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):